FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Para fines de investigación únicamente. Aviso completo →

Investigación/New Study Investigates ALN-PNP and GLP1R Agonist for Treating Fatty Liver Disease
Volver a Biblioteca de Investigación

New Study Investigates ALN-PNP and GLP1R Agonist for Treating Fatty Liver Disease

November 20, 2026
Share
Investigación Emergente

Basado en investigación emergente. Estos hallazgos son prometedores pero requieren validación adicional.

Sobre este análisis

Este artículo es un resumen AI-assisted de un reciente item de noticias o lista de ensayos clínicos. Se proporciona para ofrecer una visión rápida y accesible a la comunidad de investigación de péptidos. Para mayor precisión, siempre consulte la fuente original enlazada abajo.

New Study Investigates ALN-PNP and GLP1R Agonist for Treating Fatty Liver Disease

A new clinical trial has started to explore the potential benefits of combining a novel peptide therapy with an existing diabetes medication in treating metabolic dysfunction-associated steatotic liver disease (MASLD), commonly known as fatty liver disease. This Phase 2a study, registered on ClinicalTrials.gov under identifier NCT07527910, is being conducted by Regeneron Pharmaceuticals and aims to shed light on the effectiveness of ALN-PNP in conjunction with a GLP1R agonist like tirzepatide.

Background

Fatty liver disease affects millions of people worldwide and can lead to serious health complications if left untreated. The condition arises when fat accumulates excessively within liver cells, causing inflammation and scarring that can eventually result in cirrhosis or liver failure. Current treatments for fatty liver disease are limited, making the development of new therapies a priority.

One promising approach involves targeting the PNPLA3 protein, which is known to contribute to the progression of MASLD. ALN-PNP, the investigational drug at the heart of this study, works by reducing the production of PNPLA3 in liver cells. By lowering levels of this problematic protein, researchers hope to decrease fat accumulation and improve overall liver health.

Key Details

The Phase 2a trial will examine how ALN-PNP performs both alone and when paired with tirzepatide, a GLP1R agonist that helps regulate blood sugar levels, appetite control, and weight management. The study aims to recruit adult patients who have homozygous PNPLA3-related MASLD, meaning they carry two copies of the gene variant associated with this condition.

Participants will be randomly assigned to receive either ALN-PNP alone, ALN-PNP in combination with tirzepatide, or a placebo. Researchers will monitor changes in liver fat content and other markers of liver health over the course of the study. The primary objective is to determine if adding tirzepatide enhances the therapeutic effects of ALN-PNP on fatty liver disease.

Key Takeaways

  • New Combination Therapy: This trial explores a novel approach by combining ALN-PNP with an existing GLP1R agonist, potentially offering a more effective treatment for MASLD.
  • Targeted Protein Reduction: ALN-PNP specifically targets the PNPLA3 protein, which is implicated in the development of fatty liver disease.
  • Clinical Trial Design: The study design includes both monotherapy and combination therapy arms to assess optimal dosing strategies and efficacy.
  • Patient Inclusion Criteria: The trial focuses on patients with homozygous PNPLA3-related MASLD, providing valuable insights for this specific patient population.

What This Means

For the peptide research community, this study represents a significant step forward in understanding how targeted protein reduction can be harnessed to treat chronic liver conditions. If successful, it could pave the way for more personalized and effective treatments tailored to patients with specific genetic risk factors. Additionally, the combination of ALN-PNP with GLP1R agonists highlights the growing trend towards multi-modal therapies that address both metabolic dysfunction and liver health simultaneously.

---

Source: ClinicalTrials.gov — Published 2026-11-18

This article is for informational purposes only and does not constitute medical advice.

Nota del Editor

Este análisis fue generado usando herramientas AI y revisado por el equipo editorial de Peptide Contacts. Aunque nos esforzamos por la precisión, el contenido generado por IA puede contener errores o omisiones. Se anima a los lectores a revisar la fuente original para detalles completos, metodología y datos.

Peptide Contacts proporciona resúmenes de investigación curados para fines informativos solo. Este contenido no constituye consejo médico. Consulte siempre a un proveedor de atención médica calificado antes de tomar cualquier decisión sobre su salud.

Comments

Sign in to join the discussion

Este artículo fue generado usando IA y puede contener inexactitudes. Se proporciona para fines informativos solo y no constituye consejo médico. Verifique siempre la información con la fuente original e consulte a un proveedor de atención médica calificado antes de tomar cualquier decisión sobre su salud.